Begrüßungen: Dr. Julia Wagle,
Prof. Dr. Stefan Endres
Session I: Mechanisms of the Ubiquitin System
10:35 – 10:50
Exploiting the degradative nature of the ubiquitin system Prof. Dr. Florian Bassermann Technische Universität München
11:00 – 11:15
Structural mechanisms of E3 ligases Prof. Dr. Brenda Schulman Max-Planck-Institut Biochemie, München
11:25 – 11:40
Mechanisms of substrate recognition Sonja Lorenz Max-Planck-Institut für Multidisziplinäre Wissenschaften, Göttingen
11:50 – 12:05
Examples of successful molecular glue development (e.g. estrogen receptor) Prof. Dr. Nico Thomä Friedrich Miescher Institute for Biomedical Research, Basel
12:15 – 13:15
Mittagessen
13:15 – 13:30
The Zukunftscluster "ProxiDrugs" in the Rhein-Main region: Lessons learned since 2021 Prof. Dr. Ivan Đikić Johann Wolfgang Goethe-Universität Frankfurt am Main
13:35 – 13:55
Panel round
Targeted protein degradation – what will be the next breakthroughs?
Moderation: Prof. Dr. Florian Bassermann.
Panel: Prof. Dr. Alessio Ciulli, Prof. Dr. Ivan Đikić , Prof. Dr. Brenda Schulman, Prof. Dr. Elmar Wolf
Session II: Chemical Biology of Targeted Protein Degradation
14:00 – 14:15
PROTAC and Molecular Glue degrader design and mechanism Prof. Dr. Alessio Ciulli University of Dundee
14:25 – 14:40
PROTAC degraders - Targets Prof. Dr. Elmar Wolf Christian-Albrechts Universität zu Kiel
14:50 – 15:20
Kaffeepause
Session III: Getting PROTACs and Glues to the patient: The Challenges
15:20 – 15:35
Proximity Pharmacology Prof. Dr. Stefan Knapp Wolfgang Goethe-Universität Frankfurt am Main
15:45 – 16:00
Advancing PROTACs and Glues to Application N. N.
16:10 – 16:25
Degrader Development from the perspective of big pharma Greg Hollingworth Novartis, Basel/Cambridge
16:35 – 16:50
Keynote: The discovery of PROTAC Dr. Raymond Deshaies Amgen, USA
